CITATION REPORT List of articles citing

Comparing safety information of biosimilars with their originators: a cross-sectional analysis of European risk management plans

DOI: 10.1111/bcp.13454 British Journal of Clinical Pharmacology, 2018, 84, 738-763.

Source: https://exaly.com/paper-pdf/69656515/citation-report.pdf

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
3	Safety information reporting for biosimilars and originators. <i>Reactions Weekly</i> , 2017 , 1681, 13-13	O	
2	Comparing safety information of biosimilars with their originators: a cross-sectional analysis of European risk management plans. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 738-763	3.8	2
1	Long-term Efficacy, Safety, and Immunogenicity of the Infliximab (IFX) Biosimilar, PF-06438179/GP1111, in Patients with Rheumatoid Arthritis After Switching from Reference IFX or Continuing Biosimilar Therapy: Week 54-78 Data From a Randomized, Double-Blind, Phase III Trial.	7.9	4